Teresa Macarulla, MD, PhD

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.

Drs Macarulla and Neuzillet discuss the role of zenocutuzumab in the treatment of patients with NRG1 fusion–positive solid tumors.

Experts on pancreatic cancer review recent data on zenocutuzumab in patients with NRG1 fusion–positive GI malignancies.

Medical oncologists provide insights on the evolving molecular testing practices for NRG1 fusions.

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.